JP2023082054A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023082054A5 JP2023082054A5 JP2023047827A JP2023047827A JP2023082054A5 JP 2023082054 A5 JP2023082054 A5 JP 2023082054A5 JP 2023047827 A JP2023047827 A JP 2023047827A JP 2023047827 A JP2023047827 A JP 2023047827A JP 2023082054 A5 JP2023082054 A5 JP 2023082054A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- acid sequence
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460118P | 2017-02-17 | 2017-02-17 | |
| US62/460,118 | 2017-02-17 | ||
| JP2019544016A JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
| PCT/US2018/018557 WO2018152451A1 (en) | 2017-02-17 | 2018-02-17 | Targeted ligand-payload based drug delivery for cell therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544016A Division JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023082054A JP2023082054A (ja) | 2023-06-13 |
| JP2023082054A5 true JP2023082054A5 (https=) | 2023-07-19 |
Family
ID=63170493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544016A Active JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
| JP2023047827A Pending JP2023082054A (ja) | 2017-02-17 | 2023-03-24 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544016A Active JP7288402B2 (ja) | 2017-02-17 | 2018-02-17 | 細胞医療用の標的リガンド－ペイロードによる薬剤デリバリー |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12343403B2 (https=) |
| EP (2) | EP3583218B1 (https=) |
| JP (2) | JP7288402B2 (https=) |
| KR (1) | KR102595249B1 (https=) |
| CN (2) | CN118634339B (https=) |
| AU (1) | AU2018221171B2 (https=) |
| CA (1) | CA3053534A1 (https=) |
| ES (1) | ES3024357T3 (https=) |
| WO (1) | WO2018152451A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP2019508036A (ja) | 2016-02-16 | 2019-03-28 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫療法組成物及び方法 |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CA3053534A1 (en) * | 2017-02-17 | 2018-08-23 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| CA3096458A1 (en) | 2018-04-12 | 2019-10-17 | Umoja Biopharma, Inc. | Viral vectors and packaging cell lines |
| JP2021530444A (ja) | 2018-06-28 | 2021-11-11 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
| CN112543651B (zh) * | 2018-08-07 | 2023-06-02 | 普渡研究基金会 | 使car t细胞恢复活力 |
| MX2021008824A (es) * | 2019-01-23 | 2021-10-13 | Univ Johns Hopkins | Análogos no inmunosupresores de tacrolimus (fk506) y uso de los mismos. |
| CN114207135A (zh) | 2019-06-11 | 2022-03-18 | 夏尔人类遗传性治疗公司 | 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送 |
| WO2021044373A2 (en) * | 2019-09-06 | 2021-03-11 | Avectas Limited | Engineering of immune cells for ex vivo cell therapy applications |
| WO2021081280A1 (en) | 2019-10-23 | 2021-04-29 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| WO2022044024A1 (en) * | 2020-08-31 | 2022-03-03 | Ramot At Tel-Aviv University Ltd. | Small molecule modulators of gsk-3 activity |
| WO2022130014A1 (en) | 2020-12-16 | 2022-06-23 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
| WO2022140556A1 (en) * | 2020-12-22 | 2022-06-30 | Eutropics Pharmaceuticals, Inc. | Methods and compositions related to bcl2 and bim heterodimer antibodies |
| CN113462649B (zh) * | 2021-05-27 | 2022-08-23 | 浙江大学 | Mek抑制剂在减少car-t细胞耗竭和终末分化中的应用 |
| IL310057A (en) * | 2021-07-21 | 2024-03-01 | Immunitybio Inc | Generation of chimeric antigen receptor mRNA molecules for expression in primary NK cells |
| CN116041545A (zh) * | 2022-12-12 | 2023-05-02 | 南方医科大学 | 一种靶向荧光素或生物素的通用型car及其应用 |
| WO2024206913A2 (en) * | 2023-03-31 | 2024-10-03 | Northwestern University | Compositions for antigen-specific immune cell activation |
| WO2026012294A1 (zh) * | 2024-07-09 | 2026-01-15 | 深圳虹信生物科技有限公司 | 一种治疗b细胞过度增殖产生自身抗体所引起的疾病的药物、方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523469D0 (en) * | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| ES2502366T3 (es) * | 2001-03-09 | 2014-10-03 | Board Of Regents, The University Of Texas System | Inducción de inmunidad tumoral por variantes de proteína de unión a folato |
| US20080260812A1 (en) * | 2004-04-26 | 2008-10-23 | Takami Matsuyama C/O Kagoshima University | Therapeutic Medicine Containing Monoclonal Antibody Against Folate Receptor Beta (Fr-Beta) |
| EP2419120A4 (en) * | 2009-04-08 | 2016-01-06 | Univ California | HUMAN PROTEIN CONCERNS WITH CONTROLLED SERUM PHARMACOKINETICS |
| CA2785373A1 (en) * | 2009-12-23 | 2011-06-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| WO2016098078A2 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Dimerization switches and uses thereof |
| WO2016164745A1 (en) * | 2015-04-10 | 2016-10-13 | The Methodist Hospital System | Cd117 ligand-drug conjugates for targeted cancer therapy |
| WO2017027843A1 (en) * | 2015-08-12 | 2017-02-16 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| EP3402495A4 (en) * | 2016-01-15 | 2019-06-19 | Etubics Corporation | METHOD AND COMPOSITIONS FOR T-CELL IMMUNOTHERAPY |
| EP3529268B1 (en) * | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| LT3535392T (lt) * | 2016-11-02 | 2024-04-25 | Universität Basel | Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje |
| CA3053534A1 (en) | 2017-02-17 | 2018-08-23 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
-
2018
- 2018-02-17 CA CA3053534A patent/CA3053534A1/en active Pending
- 2018-02-17 EP EP18754879.7A patent/EP3583218B1/en active Active
- 2018-02-17 WO PCT/US2018/018557 patent/WO2018152451A1/en not_active Ceased
- 2018-02-17 CN CN202410423409.8A patent/CN118634339B/zh active Active
- 2018-02-17 JP JP2019544016A patent/JP7288402B2/ja active Active
- 2018-02-17 KR KR1020197026818A patent/KR102595249B1/ko active Active
- 2018-02-17 AU AU2018221171A patent/AU2018221171B2/en active Active
- 2018-02-17 CN CN201880024308.6A patent/CN110662839A/zh active Pending
- 2018-02-17 US US16/486,632 patent/US12343403B2/en active Active
- 2018-02-17 ES ES18754879T patent/ES3024357T3/es active Active
- 2018-02-17 EP EP25163099.2A patent/EP4600267A3/en active Pending
-
2023
- 2023-03-24 JP JP2023047827A patent/JP2023082054A/ja active Pending
-
2025
- 2025-04-30 US US19/194,112 patent/US20250262313A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023082054A5 (https=) | ||
| JP2018138049A5 (https=) | ||
| JP2019500414A5 (https=) | ||
| EP4467650A3 (en) | Scaffold proteins | |
| JP2010510315A5 (https=) | ||
| JP2017018125A5 (https=) | ||
| JP2005120106A5 (https=) | ||
| CY1112833T1 (el) | Καινοφανης προσδετης της κυτοκινης ζcυτοr17 | |
| NO20063026L (no) | Antistoffer | |
| HRP20090245T1 (en) | Pyy agonists and uses thereof | |
| JP2003515323A5 (https=) | ||
| JP2009268467A5 (https=) | ||
| DE602005020165D1 (de) | Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin | |
| JP2019214579A5 (https=) | ||
| JP2007508034A5 (https=) | ||
| MX2021004714A (es) | Proteina cas9 modificada, y uso de la misma. | |
| JP2018529626A5 (https=) | ||
| DK200601181A (da) | Fiskevaccine | |
| JPWO2020027010A5 (https=) | ||
| JP2019512693A5 (https=) | ||
| JP2006158399A5 (ja) | 細胞増殖抑制タンパク質並びにそれを用いる細胞増殖抑制剤、癌診断薬及び癌治療剤 | |
| JP2022539560A5 (https=) | ||
| JP2020127419A5 (https=) | ||
| JP2008517998A5 (https=) | ||
| JP2019038772A5 (https=) |